Clinical observation of HongjinXiaojie capsule in the treatment of hematomas after minimally invasive vacuum-assisted Mammotome mastectomy

doi:10.11958/20241932

Abstract

Abstract:

Objective To observe the efficacy of Hongjin Xiaojie capsules in treating hematoma after Mammotome minimally invasive excision and to determine the common clinical complications such as hematoma and pain after the surgery. Methods A total of 70 patients who developed hematoma within 72 hours after Mammotome minimally invasive excision for breast lumps at our hospital were selected. Based on different treatment methods, patients were divided into the observation group and the control group, with 35 cases in each group. The control group received only external hot compress treatment, while the observation group received local hot compress combined with oral administration of Hongjin Xiaojie Capsule for 4 weeks. Follow-up was conducted every 4 weeks postoperatively for a total of 12 weeks. Color ultrasound was performed to monitor the size of the hematoma. Changes in pain visual analog scale (VAS) scores and traditional Chinese medicine (TCM) syndrome scores for blood stasis were compared between the two groups of patients during follow-up. Results Four weeks after operation, the pain VAS score was significantly lower in the observation group than that in the control group [2 (1, 3) points vs. 3 (2, 4) points, P<0.05], and the proportion of hematoma was lower in the observation group than that in the control group (45.7% vs. 82.9%, P<0.05). At 12 weeks after surgery, there were no significant differences in pain scores or hematoma proportions between the two groups. The TCM symptom scores were lower in the observation group than those of the control group at 4 weeks and 12 weeks after operation (P<0.05). Conclusion Hongjin Xiaojie capsule can promote the absorption of hematoma after Mammotome surgery, effectively alleviate breast hematoma and pain, and have high safety, demonstrating broad clinical application value.

Key words: breast, hematoma, minimally invasive surgical procedures, Hongjin Xiaojie capsules, absorption and dispersion of blood stasis

CLC Number:

R271.44，R655.82

Figures/Tables 5

References 18

[1]	CHANG D H, SHU Y L. Clinic efficacy and safety of ultrasound-guided Mammotome-assisted surgery for patients with breast benign tumors[J]. Eur Rev Med Pharmacol Sci, 2023, 27(13):5985-5992. doi:10.26355/eurrev_202307_32950.
[2]	TIAN J, XU T, LIU J, et al. Efficacy of ultrasound-guided Mammotome vacuum-assisted biopsy for qualitative diagnosis of breast nodules with diameter <5 cm[J]. Altern Ther Health Med,2024:AT10671.[Epub ahead of print].
[3]	杜家笑, 党少华, 范云鹏, 等. 超声引导下麦默通乳腺微创旋切术治疗乳腺良性肿瘤的临床效果分析[J]. 延边大学医学学报, 2024, 47(3):272-274.
	DU J X, DANG S H, FAN Y P, et al. Clinical effect analysis of ultrasound-guided Mammotome minimally invasive breast resection in the treatment of benign breast tumor[J]. Journal of Medical Science Yanbian University, 2024, 47(3):272-274. doi:10.16068/j.1000-1824.2024.03.014.
[4]	来保勇, 贾丽燕, 刘宇飞, 等. 红金消结胶囊治疗乳腺增生症随机对照试验的系统评价与试验序贯分析[J]. 中国中药杂志, 2020, 45(19):4776-4783.
	LAI B Y, JIA L Y, LIU Y F, et al. Systematic review and trial sequential analysis of randomized clinical trial of Hongjin Xiaojie Capsules for treatment of hyperplastic disease of breast[J]. China Journal of Chinese Materia Medica, 2020, 45(19):4776-4783. doi:10.19540/j.cnki.cjcmm.20200221.504.
[5]	全国《中成药治疗乳腺增生症临床应用指南》课题组. 中成药治疗乳腺增生症临床应用指南(2021年版)[J]. 中国中西医结合外科杂志, 2022, 28(2):149-157.
	Research Group of National Guidelines for Clinical Application of Chinese Patent Medicines in the Treatment of Hyperplasia of Mammary Glands. Guidelines for Clinical Application of Chinese Patent Medicines in the Treatment of Hyperplasia of Mammary Glands (2021 Edition)[J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine, 2022, 28(2):149-157. doi:10.3969/j.issn.1007-6948.2022.02.001.
[6]	国家市场监督管理总局, 国家标准化管理委员会.GB/T 16751.2-中医临床诊疗术语,第2部分:证候[S]. 北京: 中国标准出版社,2021:42.
	State Administration for Market Regulation, National Standardization Administration.GB/T 16751.2-2021 Terminology of Clinical Diagnosis and Treatment in Traditional Chinese Medicine-Part 2:Syndromes[S]. Beijing: Standards Press of China, 2021:42. http://c.gb688.cn/bzgk/gb/showGb?type=online&hcno=C71A9DAD24CB1252F12439D1F045DA6A.
[7]	ZOU S F, TAO L, FENG Z C, et al. A comparative study on ultrasound-guided elite,Mammotome,and core needle biopsy for diagnosing malignant breast masses[J]. Arch Med Sci, 2022, 18(2):422-431. doi:10.5114/aoms.2019.87096.
[8]	王沛, 刘尚军, 张如辉. 乳腺良性肿块患者EnCor微创旋切术后血肿发生状况及影响因素[J]. 中国医药导报, 2022, 19(23):97-99,108.
	WANG P, LIU S J, ZHANG R H. Hematoma incidence and influencing factors in patients with benign breast masses after EnCor minimally invasive surgery[J]. China Medical Herald, 2022, 19(23):97-99,108. doi:10.20047/j.issn1673-7210.2022.23.020.
[9]	赵敏, 张步林, 何冰玲, 等. 肾上腺素在乳腺超声引导下麦默通旋切术中的应用研究[J]. 影像研究与医学应用, 2023, 7(7):191-193.
	ZHAO M, ZHANG B L, HE B L, et al. Application of epinephrine in ultrasound-guided Mammotome biopsy[J]. Journal of Imaging Research and Medical Applications, 2023, 7(7):191-193. doi:10.3969/j.issn.2096-3807.2023.07.062.
[10]	易利霞, 陈文倩, 李梦雅. 中药封包对慢性非哺乳期乳腺炎麦默通微创旋切术后疼痛及血肿的干预效果[J]. 中医药临床杂志, 2022, 34(1):172-175.
	YI L X, CHEN W Q, LI M Y. Effect of Traditional Chinese medicine package on pain and hematoma after Mammotome minimally invasive surgery for chronic non-lactation mastitis[J]. Clinical Journal of Traditional Chinese Medicine, 2022, 34(1):172-175. doi:10.16448/j.cjtcm.2022.0138.
[11]	顾燕娜, 江起庭. 芒硝外敷对乳腺良性肿块麦默通微创旋切术后疼痛及血肿的影响[J]. 中国烧伤创疡杂志, 2019, 31(1):41-45.
	GU Y N, JIANG Q T. Effect of external application of mirabilite on postoperative pain and hematoma after Mammotome minimally invasive surgery for benign breast tumor[J]. The Chinese Journal of Burns Wounds & Surface Ulcers, 2019, 31(1):41-45. doi:10.3969/j.issn.1001-0726.2019.01.009.
[12]	阮国栋, 李志安, 虞伟琴, 等. 负压引流预防乳腺麦默通切除术后血肿形成的初步临床研究[J]. 外科理论与实践, 2017, 22(5):407-410.
	RUAN G D, LI Z A, YU W Q, et al. Preliminary clinical study of negative pressure drainage to prevent hematoma formation after Mammotome mastectomy[J]. Journal of Surgery Concepts & Practice, 2017, 22(5):407-410. doi:10.16139/j.1007-9610.2017.05.010.
[13]	董云云, 张慧明, 史宪全, 等. 超声引导下乳腺良性结节微创旋切术后血肿预后及影响因素分析[J]. 中国医学装备, 2021, 18(1):81-85.
	DONG Y Y, ZHANG H M, SHI X Q, et al. Analysis of prognosis and influencing factors of hematoma after ultrasound-guided minimally invasive resection of benign breast nodules[J]. China Medical Eqipment, 2021, 18(1):81-85. doi:10.3969/J.ISSN.1672-8270.2021.01.020.
[14]	ORDER B M, SCHAEFER P J, PETERS G, et al. Evaluation of two different vacuum-assisted breast biopsy systems: Mammotome® system 11G/8G vs. ATEC^® system 12G/9G[J]. Acta Radiologica, 2013, 54(2),137-143. doi:10.1258/ar.2012.120420.
[15]	张明, 李湘奇, 王莹. 红金消结胶囊治疗乳腺增生症临床观察[J]. 光明中医, 2024, 39(6):1049-1052.
	ZHANG M, LI X Q, WANG Y. Clinical Observation on hyperplasia of mammary glands treated by Hongjin Xiaojie Capsule[J]. Guangming Journal of Chinese Medicine, 2024, 39(6):1049-1052. doi:10.3969/j.issn.1003-8914.2024.06.003.
[16]	毕聪, 吴灏, 王永刚, 等. 基于网络药理学解析复方血栓通胶囊改善微循环的作用机制[J]. 中山大学学报(自然科学版), 2022, 61(2):65-75.
	BI C, WU H, WANG Y G, et al. Mechanism of compound Xueshuantong Capsules in improving microcirculation by network pharmacology[J]. Acta Scientiarum Naturalium Universitatis Sunyatsen, 2022, 61(2):65-75. doi:10.13471/j.cnki.acta.snus.2020E024.
[17]	李章春, 孙海波, 党荣敏, 等. 五香血藤醇提物对慢性非细菌性前列腺炎大鼠的改善作用[J]. 中成药, 2022, 44(6):1950-1954.
	LI Z C, SUN H B, DANG R M, et al. Ameliorative effect of Caulis Kadsurae Longipedunculatae ethanol extract on chronic abacterial prostatitis in rats[J]. Chinese traditional patent medicine, 2022, 44(6):1950-1954. doi:10.3969/j.issn.1001-1528.2022.06.040.
[18]	陈东亮, 钟楚, 简少芬, 等. 濒危药用植物八角莲保育研究[J]. 中国现代中药, 2022, 24(3):395-402.
	CHEN D L, ZHONG C, JIAN S F, et al. Study on conservation of endangered medicinal plant Dysosma versipellis[J]. Modern Chinese Medicine, 2022, 24(3):395-402. doi:10.13313/j.issn.1673-4890.20210301003.

组别	年龄/岁	肿块数目/个	肿块长径/mm	手术时长/min
对照组	33.06±8.35	3（2，4）	17（13，23）	14（10，27）
观察组	33.46±9.79	3（2，4）	15（13，22）	20（14，30）
t或Z	0.184	0.372	0.825	1.353

组别	年龄/岁	肿块数目/个	肿块长径/mm	手术时长/min
对照组	33.06±8.35	3（2，4）	17（13，23）	14（10，27）
观察组	33.46±9.79	3（2，4）	15（13，22）	20（14，30）
t或Z	0.184	0.372	0.825	1.353

组别	n	术后72 h	术后4周	术后12周
对照组	35	4.06±1.45	3（2，4）	1（0，1）
观察组	35	4.14±1.56	2（1，3）^a	1（0，1）
t或Z		0.238	3.824^＊	1.062

组别	n	术后72 h	术后4周	术后12周
对照组	35	4.06±1.45	3（2，4）	1（0，1）
观察组	35	4.14±1.56	2（1，3）^a	1（0，1）
t或Z		0.238	3.824^＊	1.062

组别	n	术后4周	术后12周
对照组	35	29（82.9）	6（17.1）
观察组	35	16（45.7）	5（14.3）
χ²		10.516^＊	0.108